Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia

Dongsheng Xu, Cynthia Schultz, Yelena Akker, Linda Cannizzaro, K.h. Ramesh, Juan Du, Howard Ratech

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with frequent cytogenetic abnormalities. They can arise de novo or be related to therapy. Although blasts in MDS have been studied extensively, there is little information available on the mature, non-blast myeloid cells (NBMCs). We used a retrospective case-control study design. NBMC populations in MDS (48 cases) and in tumor-free control (12 cases) bone marrow samples were analyzed using multiparameter flow cytometry for mean side scatter (SSC) channel number and for expression of aberrant cell surface antigens. MDS cases were stratified on the basis of cytogenetic abnormalities. We report that NBMCs in MDS with normal karyotype expressed significantly higher HLA-DR than controls (P = 0.034). NBMCs in MDS cases with cytogenetic abnormalities and with ≥5% marrow blasts, compared with controls, had significantly higher CD34 and higher HLA-DR but lower CD10 and lower SSC mean channel number. CD34 expression in NBMCs was significantly greater in therapy-related MDS compared with de novo MDS (P = 0.01), although the presence of cytogenetic abnormalities was not different (P > 0.05). These data suggest that bone marrow, mature, NBMCs have phenotypic changes in MDS that are not seen in normal controls.

Original languageEnglish (US)
Pages (from-to)9-16
Number of pages8
JournalAmerican Journal of Hematology
Volume74
Issue number1
DOIs
StatePublished - Sep 1 2003

Fingerprint

Myelodysplastic Syndromes
Myeloid Cells
Antigens
Chromosome Aberrations
Bone Marrow
HLA-DR Antigens
Surface Antigens
Hematopoietic Stem Cells
Karyotype
Case-Control Studies
Flow Cytometry
Therapeutics

Keywords

  • Aberrant antigens
  • Cytogenetics
  • Flow cytometry
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. / Xu, Dongsheng; Schultz, Cynthia; Akker, Yelena; Cannizzaro, Linda; Ramesh, K.h.; Du, Juan; Ratech, Howard.

In: American Journal of Hematology, Vol. 74, No. 1, 01.09.2003, p. 9-16.

Research output: Contribution to journalArticle

Xu, Dongsheng ; Schultz, Cynthia ; Akker, Yelena ; Cannizzaro, Linda ; Ramesh, K.h. ; Du, Juan ; Ratech, Howard. / Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. In: American Journal of Hematology. 2003 ; Vol. 74, No. 1. pp. 9-16.
@article{d23c47347c7d42afbaabf977e5d5d3e0,
title = "Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia",
abstract = "Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with frequent cytogenetic abnormalities. They can arise de novo or be related to therapy. Although blasts in MDS have been studied extensively, there is little information available on the mature, non-blast myeloid cells (NBMCs). We used a retrospective case-control study design. NBMC populations in MDS (48 cases) and in tumor-free control (12 cases) bone marrow samples were analyzed using multiparameter flow cytometry for mean side scatter (SSC) channel number and for expression of aberrant cell surface antigens. MDS cases were stratified on the basis of cytogenetic abnormalities. We report that NBMCs in MDS with normal karyotype expressed significantly higher HLA-DR than controls (P = 0.034). NBMCs in MDS cases with cytogenetic abnormalities and with ≥5{\%} marrow blasts, compared with controls, had significantly higher CD34 and higher HLA-DR but lower CD10 and lower SSC mean channel number. CD34 expression in NBMCs was significantly greater in therapy-related MDS compared with de novo MDS (P = 0.01), although the presence of cytogenetic abnormalities was not different (P > 0.05). These data suggest that bone marrow, mature, NBMCs have phenotypic changes in MDS that are not seen in normal controls.",
keywords = "Aberrant antigens, Cytogenetics, Flow cytometry, Myelodysplastic syndrome",
author = "Dongsheng Xu and Cynthia Schultz and Yelena Akker and Linda Cannizzaro and K.h. Ramesh and Juan Du and Howard Ratech",
year = "2003",
month = "9",
day = "1",
doi = "10.1002/ajh.10372",
language = "English (US)",
volume = "74",
pages = "9--16",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia

AU - Xu, Dongsheng

AU - Schultz, Cynthia

AU - Akker, Yelena

AU - Cannizzaro, Linda

AU - Ramesh, K.h.

AU - Du, Juan

AU - Ratech, Howard

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with frequent cytogenetic abnormalities. They can arise de novo or be related to therapy. Although blasts in MDS have been studied extensively, there is little information available on the mature, non-blast myeloid cells (NBMCs). We used a retrospective case-control study design. NBMC populations in MDS (48 cases) and in tumor-free control (12 cases) bone marrow samples were analyzed using multiparameter flow cytometry for mean side scatter (SSC) channel number and for expression of aberrant cell surface antigens. MDS cases were stratified on the basis of cytogenetic abnormalities. We report that NBMCs in MDS with normal karyotype expressed significantly higher HLA-DR than controls (P = 0.034). NBMCs in MDS cases with cytogenetic abnormalities and with ≥5% marrow blasts, compared with controls, had significantly higher CD34 and higher HLA-DR but lower CD10 and lower SSC mean channel number. CD34 expression in NBMCs was significantly greater in therapy-related MDS compared with de novo MDS (P = 0.01), although the presence of cytogenetic abnormalities was not different (P > 0.05). These data suggest that bone marrow, mature, NBMCs have phenotypic changes in MDS that are not seen in normal controls.

AB - Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with frequent cytogenetic abnormalities. They can arise de novo or be related to therapy. Although blasts in MDS have been studied extensively, there is little information available on the mature, non-blast myeloid cells (NBMCs). We used a retrospective case-control study design. NBMC populations in MDS (48 cases) and in tumor-free control (12 cases) bone marrow samples were analyzed using multiparameter flow cytometry for mean side scatter (SSC) channel number and for expression of aberrant cell surface antigens. MDS cases were stratified on the basis of cytogenetic abnormalities. We report that NBMCs in MDS with normal karyotype expressed significantly higher HLA-DR than controls (P = 0.034). NBMCs in MDS cases with cytogenetic abnormalities and with ≥5% marrow blasts, compared with controls, had significantly higher CD34 and higher HLA-DR but lower CD10 and lower SSC mean channel number. CD34 expression in NBMCs was significantly greater in therapy-related MDS compared with de novo MDS (P = 0.01), although the presence of cytogenetic abnormalities was not different (P > 0.05). These data suggest that bone marrow, mature, NBMCs have phenotypic changes in MDS that are not seen in normal controls.

KW - Aberrant antigens

KW - Cytogenetics

KW - Flow cytometry

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0042925579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042925579&partnerID=8YFLogxK

U2 - 10.1002/ajh.10372

DO - 10.1002/ajh.10372

M3 - Article

VL - 74

SP - 9

EP - 16

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -